Bluejay Diagnostics, Inc.
BJDXNASDAQHealthcare● Active
$5.23
+$0.43(+8.96%)
Market Cap$2372019
P/E Ratio—
52W High$16.68
52W Low$1.623
Bluejay Diagnostics, Inc. (BJDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BJDX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.95
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
BJDX reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 19, 2026 | -$3520.00 | — | — | — | — | — |
| — Q2 FY2026 | May 13, 2026 | — | -$1.95 | — | — | — | — |
| — Q1 FY2026 | Mar 6, 2026 | — | -$2.37 | — | — | — | — |
| — Q4 FY2025 | Nov 7, 2025 | — | -$4.04 | — | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | — | -$1.41 | — | — | — | — |
| — Q2 FY2025 | May 13, 2025 | — | -$3.37 | — | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$144.00 | -$112.37 | +22.0% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$144.00 | -$8.00 | +94.4% | — | — | — |
Q3 FY2026
Aug 19, 2026
EPS Actual
—
EPS Est.
-$3520.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026
EPS Actual
-$1.95
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 6, 2026
EPS Actual
-$2.37
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 7, 2025
EPS Actual
-$4.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
-$1.41
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$3.37
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$112.37
EPS Est.
-$144.00
EPS Surpr.
+22.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$8.00
EPS Est.
-$144.00
EPS Surpr.
+94.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $-144.00 | $-144.00 | $-144.00 | 1 |
| Q1 FY2029 | $-144.00 | $-144.00 | $-144.00 | 1 |
| Q4 FY2028 | $-144.00 | $-144.00 | $-144.00 | 1 |
| Q3 FY2028 | $-1152.00 | $-1152.00 | $-1152.00 | 1 |
| Q2 FY2028 | $-832.00 | $-832.00 | $-832.00 | 1 |
| Q1 FY2028 | $-1304.00 | $-1304.00 | $-1304.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 13, 2026 | — | $1.79 | $1.78 | -0.56% |
| — Q1 FY2026 | Mar 6, 2026 | — | $1.90 | $1.86 | -2.11% |
| — Q4 FY2025 | Nov 7, 2025 | — | $6.36 | $6.28 | -1.26% |
| — Q3 FY2025 | Aug 7, 2025 | — | $5.88 | $5.88 | +0.00% |
| — Q2 FY2025 | May 13, 2025 | — | $7.12 | $7.24 | +1.69% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +22.0% | $15.24 | $14.92 | -2.10% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +94.4% | $18.40 | $18.52 | +0.65% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -77.8% | $66.80 | $59.56 | -10.84% |
Q2 FY2026-0.56%
Report Date
May 13, 2026
EPS Beat/Miss
—
Price Before
$1.79
Price After
$1.78
Q1 FY2026-2.11%
Report Date
Mar 6, 2026
EPS Beat/Miss
—
Price Before
$1.90
Price After
$1.86
Q4 FY2025-1.26%
Report Date
Nov 7, 2025
EPS Beat/Miss
—
Price Before
$6.36
Price After
$6.28
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
—
Price Before
$5.88
Price After
$5.88
Q2 FY2025+1.69%
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$7.12
Price After
$7.24
Q1 FY2025-2.10%
Report Date
Mar 31, 2025
EPS Beat/Miss
+22.0%
Price Before
$15.24
Price After
$14.92
Q4 FY2024+0.65%
Report Date
Nov 7, 2024
EPS Beat/Miss
+94.4%
Price Before
$18.40
Price After
$18.52
Q3 FY2024-10.84%
Report Date
Aug 14, 2024
EPS Beat/Miss
-77.8%
Price Before
$66.80
Price After
$59.56
Avg Beat Reaction-0.73%
Avg Miss Reaction-10.84%
Beat Rate2 / 8 quarters
Largest Move-10.84% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BJDX ends December
Bluejay Diagnostics, Inc. (BJDX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.95 (in line with the analyst consensus of —). BJDX has beaten EPS estimates for 2 consecutive quarters. The next BJDX earnings date is expected around September 1, 2026.
Each quarter, investors track BJDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BJDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BJDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BJDX earnings · 4 questionsBluejay Diagnostics, Inc.'s next earnings report is expected around September 1, 2026. BJDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BJDX historically reports after market close (AMC).
BJDX earnings datewhen is BJDX earningsBJDX next earnings datewhen does BJDX report earningsBJDX earnings calendar
▸ Source: FMP · Bluejay Diagnostics, Inc. SEC filings · US GAAP · Bluejay Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026